Cavalieri Stefano, Filippini Daria Maria, Ottini Arianna, Bergamini Cristiana, Resteghini Carlo, Colombo Elena, Lombardo Roberta, Nuzzolese Imperia, Alfieri Salvatore, Licitra Lisa, Locati Laura D
Head and Neck Cancer Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, via Venezian 1, 20133 Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, via Festa del Perdono 7, 20122 Milan, Italy.
Explor Target Antitumor Ther. 2021;2(6):522-542. doi: 10.37349/etat.2021.00062. Epub 2021 Dec 31.
The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In recent years, the deeper and increasing knowledge on the genomic landscape and the upcoming new data on immunotherapy enacted by HNSCCs have led to successful therapeutic targeting of the immune system. Immune checkpoint inhibitors (ICIs) have changed state of the art in R/M patients and could have a potential role even in early disease. The purpose of this work is to summarize the role of immunotherapy for R/M HNSCC in clinical practice, with insights about future perspectives. Updated immunotherapy results in other R/M head and neck cancers such as thyroid, salivary glands, nasopharynx, sinonasal cancers, and nuclear protein in testis (NUT) are presented.
复发性/转移性（R/M）头颈部鳞状细胞癌（HNSCC）的预后不佳，促使细胞毒性癌症治疗之外的治疗方法领域取得了最新进展。近年来，对基因组格局的深入了解不断增加，以及HNSCC引发的免疫治疗方面即将出现的新数据，都促成了对免疫系统的成功靶向治疗。免疫检查点抑制剂（ICI）改变了R/M患者的治疗现状，甚至在早期疾病中也可能发挥潜在作用。这项工作的目的是总结免疫治疗在R/M HNSCC临床实践中的作用，并对未来前景进行深入探讨。文中还展示了免疫治疗在其他R/M头颈癌（如甲状腺癌、唾液腺癌、鼻咽癌、鼻窦癌和睾丸核蛋白（NUT）癌）中的最新结果。
